Trial Profile
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML) and Cataloging the Molecular Consequences of JAK2 Inhibition in Chronic Myelomonocytic Leukemia: A Correlative Study Identifying Targetable CMML Sub-Clones by Leveraging GM-CSF Dependent pSTAT Hypersensitivity
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Sep 2022
Price :
$35
*
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Chronic myelomonocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 09 Sep 2022 Status changed from active, no longer recruiting to completed.
- 28 Dec 2021 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 12 Jul 2021 Primary endpoint (Occurrence of Clinical Response) has been met, as per results published in the Clinical Cancer Research.